Melanotan II Research & Studies
We track 20 published, PubMed-indexed studies for Melanotan II, spanning 1996 to 2026. The research below includes 10 research articles, 8 reviews, 2 clinical trials.
These summaries are for educational purposes. Research findings, particularly from preclinical studies, may not translate to human outcomes. Always consult a qualified healthcare provider before making decisions based on this information.
10
Research Articles
8
Reviews
2
Clinical Trials
Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report.
Research ArticleBonchev A|Life (Basel)|2026
Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?
Research ArticleYassin Alsabbagh A, Bhujel N, Singh RP|Int J Oral Maxillofac Surg|2025
5-Hydroxypyrroloindoline Affords Tryptathionine and 2,2'-bis-Indole Peptide Staples: Application to Melanotan-II.
Research ArticleTodorovic M, Blanc A, et al.|Chemistry|2024
Melanotan-II reverses memory impairment induced by a short-term HF diet.
Research ArticleWekwejt P, Wojda U, Kiryk A|Biomed Pharmacother|2023
CLIPSing Melanotan-II to Discover Multiple Functionally Selective hMCR Agonists.
Research ArticleTomassi S, Dimmito MP, et al.|J Med Chem|2022
Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for food.
Research ArticleEliason NL, Martin L, et al.|Neuropeptides|2022
Role of Temozolomide Regimen on Survival Outcomes in Molecularly Stratified WHO Grade II Gliomas: A Systematic Review.
ReviewGhaffari-Rafi A, Ghaffari-Rafi S, Leon-Rojas J|Asian J Neurosurg|2021
Melanotan II User Experience: A Qualitative Study of Online Discussion Forums.
Research ArticleGilhooley E, Daly S, McKenna D|Dermatology|2021
Melanotan II, a melanocortin agonist, partially rescues the impaired thermogenic capacity of pituitary adenylate cyclase-activating polypeptide deficient mice.
Research ArticleMcMillan TR, Forster MAM, et al.|Exp Physiol|2021
LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs.
Research ArticleMestria S, Odoardi S, et al.|Drug Test Anal|2021
Melanotan Tanning Injection: A Rare Cause of Priapism.
Research ArticleMallory CW, Lopategui DM, Cordon BH|Sex Med|2021
Melanotan II: a possible cause of renal infarction: review of the literature and case report.
ReviewPeters B, Hadimeri H, et al.|CEN Case Rep|2020
Effect of Treatment Modalities on Progression-Free Survival and Overall Survival in Molecularly Subtyped World Health Organization Grade II Diffuse Gliomas: A Systematic Review.
ReviewGhaffari-Rafi A, Samandouras G|World Neurosurg|2020
Melanotan-induced priapism: a hard-earned tan.
ReviewDreyer BA, Amer T, Fraser M|BMJ Case Rep|2019
Metallothionein in Brain Disorders.
ReviewJuárez-Rebollar D, Rios C, et al.|Oxid Med Cell Longev|2017
Protective role of metallothionein in chemical and radiation carcinogenesis.
ReviewFujiwara Y, Satoh M|Curr Pharm Biotechnol|2013
A review of metallothionein isoforms and their role in pathophysiology.
ReviewThirumoorthy N, Shyam Sunder A, et al.|World J Surg Oncol|2011
Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II.
Clinical TrialWessells H, Levine N, et al.|Int J Impot Res|2000
Discovery and development of novel melanogenic drugs. Melanotan-I and -II.
ReviewHadley ME, Hruby VJ, et al.|Pharm Biotechnol|1998
Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.
Clinical TrialDorr RT, Lines R, et al.|Life Sci|1996